Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.
Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S.
Sasaki K, et al. Among authors: ravandi f.
Leuk Lymphoma. 2015 Jul;56(7):2092-7. doi: 10.3109/10428194.2014.984703. Epub 2015 Feb 17.
Leuk Lymphoma. 2015.
PMID: 25641433
Free PMC article.
Clinical Trial.